FDA Warning Letter Alleges Empower Pharmacy's Compounded Semaglutide and Tirzepatide Are Illegal Copies of Approved GLP-1 Drugs

The FDA has escalated its scrutiny of compounded weight-loss drugs, this time aiming at one of the largest pharmacies that supplies the telehealth market. In a warning letter dated September 18, 2026, and made public on September 23, the agency told Empower Pharmacy that its compounded versions of two blockbuster GLP-1 medicines appear to be illegal copies of the approved drugs, and that its added vitamins do not change that. The letter reaches a business model that has fueled much of the low-cost online supply of GLP-1s. This is general information, not medical or legal advice.

What the warning letter says

The FDA addressed Warning Letter #738238 to Arta Shaun Noorian, founder and chief executive of Empower Clinic Services, LLC, which does business as Empower Pharmacy in Houston, Texas. It follows an inspection of the facility from November 3 to 14, 2025, after which investigators issued a Form FDA 483 on November 14, 2025. The company submitted written responses dated December 8, 2025, March 18, 2026, and April 30, 2026, which the FDA reviewed and found insufficient on the central points. The letter alleges violations of sections 501(a)(2), 502(f)(1), and 505 of the Federal Food, Drug, and Cosmetic Act.

Two product lines are at the center of the letter. The FDA identifies compounded tirzepatide mixed with niacinamide (a form of vitamin B3) and compounded semaglutide mixed with cyanocobalamin (vitamin B12), in specified strengths and vial sizes. Tirzepatide is the active ingredient in Eli Lilly's approved products, and semaglutide is the active ingredient in Novo Nordisk's, per the Associated Press.

The 'essentially a copy' allegation

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy may compound a drug for an individual patient, but it generally may not compound a product that is essentially a copy of a commercially available approved drug on a regular basis or in inordinate amounts. The FDA alleges Empower did exactly that: it wrote that the firm compounded drug products that are essentially copies of commercially available drug products regularly and in inordinate amounts.

The added vitamins are what compounders often point to as the clinical difference that takes a product outside the copy rule. The FDA rejected that rationale here. In a line quoted by the Associated Press, the agency wrote that the volume of products being produced suggests that the differences between the compounded products and the FDA-approved products are pretextual. The letter also flags prescriber determinations of a 'significant difference' that the FDA found repeated verbatim across many records, which the agency treated as pre-generated language rather than individualized clinical judgment.

Sterility and manufacturing concerns

Beyond the copy question, the FDA raised safety concerns about how the injectable drugs were made. The letter states that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth, tracking the language of section 501(a)(2)(A). The agency cited current good manufacturing practice deficiencies under 21 CFR parts 210 and 211.

• Inadequate airflow validation studies for aseptic areas.
• Media fill simulations that the FDA viewed as not sufficiently challenging.
• Equipment and facility maintenance gaps affecting aseptic conditions.
• Weak environmental monitoring and quality-control-unit oversight.

Empower's response

Empower said it is cooperating. Chief executive Arta Shaun Noorian told the Associated Press that the company takes compliance seriously, has already remediated many of the issues outlined in the warning letter, and will continue to work cooperatively with the agency. The FDA asked Empower to respond in writing within 15 working days, referencing Warning Letter #738238, and to explain the specific steps it has taken to correct the alleged violations and prevent their recurrence.

The action is significant because of Empower's scale. The company dispensed nearly 3 million prescriptions in the first 10 months of 2024, with most of its revenue coming from GLP-1 drugs, according to the Associated Press. The letter is the latest in a series of FDA actions involving Empower, which the wire service described as the company's fifth warning letter since 2017.

Why this matters for telehealth GLP-1 patients

Much of the affordable online supply of semaglutide and tirzepatide has run through large compounders selling to or through telehealth platforms. Compounded drugs are not FDA approved, and the agency has repeatedly warned that they do not carry the same manufacturing, testing, and safety-monitoring assurances as approved products. The FDA has logged more than 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026, though such reports do not by themselves establish that a product caused harm.

This warning letter does not by itself pull any product from the market or decide any question in court. What it signals is the FDA's position that adding a vitamin to a high-volume GLP-1 formulation does not, on its own, make the product something other than a copy of the approved drug. Patients weighing compounded versus approved GLP-1 options should discuss the tradeoffs with a licensed clinician and pharmacist. For a broader view of the regulated market, see our weight-loss hub.

What a warning letter is, and its limits

A warning letter is the FDA's formal notice of alleged violations found during a review. It asks the recipient to correct the problems and reply, and the company can remediate or contest the agency's reading. It is not a court judgment, and it does not establish that a violation occurred. The FDA has not announced fines, seizures, or a court case tied to this letter. Whether Empower's added-vitamin formulations qualify as permissible compounded products or as unlawful copies remains contested between the company and the agency. Because production and labeling practices can change after an inspection, the operative facts for any decision live in the FDA letter itself and in the company's responses, not in a news summary. This is general information, not medical or legal advice.